Double-blind randomized crossover study comparing intracorporeal prostaglandin E1
with combination of prostaglandin E1 and lidocaine in the treatment of organic
impotence.
Author(s): Kattan S.
Affiliation(s): Department of Surgery, King Saud University, Riyadh, Saudi Arabia.
Publication date & source: 1995, Urology. , 45(6):1032-6
OBJECTIVES: To study the efficacy of lidocaine 1% in relieving pain associated
with intracorporeal prostaglandin E1 and to assess its effect on the
pharmacological erection.
METHODS: Twenty-two patients who had previously experienced pain with
intracorporeal prostaglandin E1 injections were submitted to a double-blind
randomized crossover study to evaluate comparatively the effects of
intracorporeal prostaglandin E1 alone and in combination with lidocaine. The
signed rank test was used for statistical analysis of the results.
RESULTS: With prostaglandin E1 monotherapy (20 micrograms) 86.3% of patients
experienced pain and 27.2% had an adequate erection. With combination therapy
(prostaglandin E1 20 micrograms plus lidocaine 1% 1 cc) 45.4% of patients
experienced pain and 57.8% of patients had improvement of pain compared with
prostaglandin E1 monotherapy. The adequate erectile response rate with
combination therapy was 63.6%; in addition, 31.8% of patients noted enhancement
in the duration of erection. The signed rank test was significant for the pain
response (P < 0.01) and for the degree of erection (P < 0.01). The signed rank
test was not, however, significant for the increase in duration of erection after
combination therapy. No significant side effects were noted after either
injection.
CONCLUSIONS: Lidocaine 1% can be safely and usefully combined with intracorporeal
prostaglandin E1 in the treatment of erectile dysfunction with alleviation of
pain and enhancement of erectile effect.
|